0001610717-24-000341.txt : 20240617
0001610717-24-000341.hdr.sgml : 20240617
20240617164324
ACCESSION NUMBER: 0001610717-24-000341
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240613
FILED AS OF DATE: 20240617
DATE AS OF CHANGE: 20240617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gould Terry P
CENTRAL INDEX KEY: 0001553470
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37719
FILM NUMBER: 241048893
MAIL ADDRESS:
STREET 1: C/O ONCOMED PHARMACEUTICALS, INC.
STREET 2: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Corvus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001626971
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464670809
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 863 MITTEN ROAD
STREET 2: SUITE 102
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: (650) 900-4520
MAIL ADDRESS:
STREET 1: 863 MITTEN ROAD
STREET 2: SUITE 102
CITY: BURLINGAME
STATE: CA
ZIP: 94010
4
1
form4.xml
X0508
4
2024-06-13
0001626971
Corvus Pharmaceuticals, Inc.
CRVS
0001553470
Gould Terry P
C/O CORVUS PHARMACEUTICALS, INC.
863 MITTEN ROAD, SUITE 102
BURLINGAME
CA
94010
true
true
false
Common Stock, $0.0001 par value
3275616
I
By Funds
Stock Option (Right to Buy)
2.12
2024-06-13
4
A
0
15000
0
A
2034-06-13
Common Stock
15000
15000
D
Represents 694,854 shares held by Adams Street 2011 Direct Fund LP ("AS 2011"), 715,361 shares held by Adams Street 2012 Direct Fund LP ("AS 2012"), 541,133 shares held by Adams Street 2013 Direct Fund LP ("AS 2013"), 736,033 shares held by Adams Street 2014 Direct Fund LP ("AS 2014"), 69,864 shares held by Adams Street 2015 Direct Venture/Growth Fund LP ("AS 2015"), 67,769 shares held by Adams Street 2016 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2017"), 126,806 shares held by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2018") and 236,128 shares held by Adams Street Venture/Growth VI LP ("ASVG VI").
Adams Street Partners, LLC, as the managing member of the general partner of the general partner of each of AS 2011, AS 2012, AS 2013, AS 2014, AS 2015, AS 2016, AS 2017, AS 2018 and ASVG VI (collectively the "Funds"), may be deemed to beneficially own the shares held by the Funds. Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. (Terry) Gould, Robin Murray and Fred Wang, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by the Funds. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. Gould, Robin Murray and Fred Wang disclaim beneficial ownership of the shares held by the Funds except to the extent of their pecuniary interest therein.
The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
This option was granted to Elisha P. Gould, a director of Corvus Pharmaceuticals, Inc., who is a partner of Adams Street Partners, LLC. Adams Street Partners, LLC is the managing member of the general partner of the general partner of each of the Funds. By agreement with the Funds, Mr. Gould is deemed to hold the option for the benefit of the Funds. The option may be deemed to be indirectly beneficially owned by Adams Street Partners, LLC. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. Gould, Robin Murray and Fred Wang, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), disclaim beneficial ownership of the option except to the extent of the pecuniary interest therein.
/s/ Leiv Lea, as Attorney-in-Fact for Terry P. Gould
2024-06-17